Regeneron Pharmaceuticals | REGN - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 58.94B 4.03B 2025-12
Agenus USD 169.66M 146.06M 2025-12
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Amgen USD 51.89B 1.88B 2026-03
Astellas Pharma JPY 320B 0 2026-03
AstraZeneca USD 25.96B 177M 2026-03
Biogen USD 6.29B 1.7M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Eli Lilly USD 39.37B 1.5B 2026-03
Esperion Therapeutics USD 457.65M 9.5M 2025-12
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Incyte USD 29.41M 785K 2026-03
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
J&J USD 37.53B 1.91B 2026-03
Kyowa Hakko Kirin JPY 24.12B 5.27B 2024-12
Merck USD 46.67B 77M 2026-03
Moderna USD 603M 7M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.45B 7.86B 2026-03
Novartis USD 29.59B 5.35B 2025-12
Pfizer USD 60.57B 1.08B 2026-03
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sanofi EUR 15.72B 150.06M 2025-12
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Teva Pharmaceutical Industries USD 14.02B 971M 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
United Therapeutics USD 100M 100M 2024-06
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12